News|Articles|May 25, 2016

Bio Pharma Reforms in China

External Link - PT0516 CPhIChina DD pr2f-Web.pdf

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia recieved accelerated approval from the FDA.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

ByZachary Zubulake

August 20th 2026

Pasatru (garetosmab-grts) has been approved by the FDA to treat symptoms of fibrodysplasia ossificans progressiva

How a 63-Patient Trial Delivered an FDA Approval

ByZachary Zubulake

August 20th 2026

Ask the Expert: Complying with Standards

BySusan J. Schniepp,Siegfried Schmitt,Susan Haigney

August 20th 2026

FDA concept | Concept of the Food and Drug Administration. Magnifier glass, folder and clock | Image Credit © Sviatlana - stock.adobe.com

What Does Overton's FDA Nomination Mean for Drug Reviews?

ByZachary Zubulake

August 19th 2026

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway

ByZachary Zubulake

August 19th 2026

Bio Pharma Reforms in China

Related Content

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

How a 63-Patient Trial Delivered an FDA Approval

Ask the Expert: Complying with Standards

What Does Overton's FDA Nomination Mean for Drug Reviews?

Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway

Trending on Pharmaceutical Technology

How AI Can Assist with Post-Marketing Changes

What Does Overton's FDA Nomination Mean for Drug Reviews?

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

Ask the Expert: Complying with Standards

How a 63-Patient Trial Delivered an FDA Approval